SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine

SOHPIA Study in Metastatic Breast Cancer #SABCS19 @UCSFMedicine

User Photo
SABCS

9 months
63 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Hope Rugo, MD of @UCSFMedicine discusses the SOPHIA Study.

_____________

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today presented updated results from the Phase 3 SOPHIA study comparing margetuximab plus chemotherapy versus trastuzumab plus chemotherapy in patients with HER2-positive metastatic breast cancer who have previously been treated with anti-HER2-targeted therapies. Margetuximab is an investigational, immune-enhancing monoclonal antibody derived from the Company’s proprietary Fc-engineering technology platform. The data were presented today during an oral session at the San Antonio Breast Cancer Symposium (SABCS) by Dr. Hope Rugo, M.D., Director, Breast Oncology and Clinical Trials Education, University of California San Francisco Helen Diller Family Comprehensive Cancer Center.

"Patients with later stage HER2-positive metastatic breast cancer need access to new therapies. The updated SOPHIA study results presented today at the second interim survival analysis showed a trend in overall survival favoring margetuximab and are encouraging. Furthermore, margetuximab is the only HER2-targeted agent to show PFS superiority versus trastuzumab in a head-to-head Phase 3 clinical trial," said Dr. Rugo. "The SOPHIA study also includes a pre-specified analysis of CD16A genotype as a predictor of anti-HER2 antibody efficacy, which although exploratory, is the first such prospective clinical analysis and suggests differential benefit in this population."

Read here: https://www.oncologytube.com/video/macrogenics-presents-results-from-the-sophia-study-of-margetuximab-in-patients-with-her2-positive-metastatic-breast-cancer-at-the-san-antonio-breast-cancer-symposium

Up Next Autoplay